Vaccine-boosted CAR T crosstalk with host immunity to reject tumors with antigen heterogeneity

Chimeric Antigen Receptor (CAR) T-cell therapy effectively treats human cancer, but loss of the antigen recognized by the CAR poses a major obstacle. We found that in vivo vaccine boosting of CAR T-cells triggers engagement of the endogenous immune system to circumvent antigen-negative tumor escape....

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Leyuan, Hostetler, Alexander, Morgan, Duncan M., Maiorino, Laura, Sulkaj, Ina, Whittaker, Charles A., Neeser, Alexandra, Pires, Ivan Susin, Yousefpour, Parisa, Gregory, Justin, Qureshi, Kashif, Dye, Jonathan, Abraham, Wuhbet, Suh, Heikyung, Li, Na, Love, J. Christopher, Irvine, Darrell J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10372881/
https://www.ncbi.nlm.nih.gov/pubmed/37413990
http://dx.doi.org/10.1016/j.cell.2023.06.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10372881/
https://www.ncbi.nlm.nih.gov/pubmed/37413990
http://dx.doi.org/10.1016/j.cell.2023.06.002

Ejemplares similares